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Abstract
Purpose: To detect differences in global brain volumes and identify relations between brain
volume and appetite-related hormones in women with polycystic ovary syndrome (PCOS)
compared to body mass index-matched controls.
Methods: Forty subjects participated in this study. Cranial magnetic resonance imaging and
measurements of fasting ghrelin, leptin and glucagon-like peptide 1 (GLP-1), as well as GLP-1
levels during mixed-meal tolerance test (MTT), were performed.
Results: Total brain volume and total gray matter volume (GMV) were decreased in obese PCOS
compared to obese controls (p50.05 for both) whereas lean PCOS and controls did not show a
significant difference. Secondary analyses of regional brain volumes showed decreases in GMV
of the caudate nucleus, ventral diencephalon and hippocampus in obese PCOS compared to
obese controls (p50.05 for all), whereas lean patients with PCOS had lower GMV in the
amygdala than lean controls (p50.05). No significant relations were detected between
structural differences and measured hormone levels at baseline or during MTT.
Conclusion: This study, investigating structural brain alterations in PCOS, suggests volumetric
reductions in global brain areas in obese women with PCOS. Functional studies with larger
sample size are needed to determine physiopathological roles of these changes and potential
effects of long-term medical management on brain structure of PCOS.
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Introduction
Polycystic ovary syndrome (PCOS), the most common reproduct-
ive endocrinopathy in women of childbearing age, is closely related
with obesity and metabolic dysfunction [1]. A similar increase in
the prevalence of PCOS and obesity generated thoughts that these
disorders might have a cause and effect relationship [2].
Obesity is a global epidemic, closely related with diseases
causing an increase in morbidity and mortality [3]. Despite fast-
food restaurants and presentation of food in large portions, not
everybody to become obese could be related to individual
differences in eating behavior and susceptibility to environmental
factors [4]. Food intake is controlled centrally by two comple-
mentary systems which are known as homeostatic and hedonic
systems. The homeostatic system is responsible for creating
balance according to energy demands of the body and controlled
mainly by hypothalamus [5]. The hedonic system is responsible
for reward-related food intake and it is closely related with
amygdala, striatum, insula and orbitofrontal cortex (OFC) [6].
Those areas related with homeostatic and hedonic systems are
important parts of gray matter in the central nervous system
(CNS). These systems are also closely related with hormones,
most well-known being an adipocyte-derived hormone leptin,
which informs the brain about long-term energy stores. Ghrelin
and glucagon-like peptide-1 (GLP-1) are among other members of
these systems and they are responsible for providing information
about short-term energy status [5,6].
Neuroimaging is a widely used technique in obesity research in
order to understand neurological basis of appetite and body
weight [7]. By using cranial magnetic resonance imaging (MRI),
global and regional volume measurements could be performed
[8]. Alterations of the complex relationship between neuronal and
hormonal systems in disorders such as PCOS and obesity may
cause a tendency to weight gain. Major areas involved in appetite
regulation, eating behavior and energy balance are hypothalamus,
insula, OFC, ventral striatum (nucleus accumbens), dorsal
striatum (putamen and nucleus caudatus), amygdala and hippo-
campus [9]. These regions are also important to include receptors
of appetite hormones or to show signal changes due to hormonal
effects by using functional MRI (fMRI) techniques [9,10].
Hypothalamus, nucleus caudatus, putamen, nucleus accumbens,
amygdala and hippocampus were shown to have receptors of
leptin, GLP-1 and ghrelin or show signal change in fMRI with
stimulation with these hormones [11–14]. Overall, appetite and
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regulation of food intake is detected centrally by the hypothal-
amus and reward-related areas and peripherally by adipose tissue
and gastrointestinal system. Understanding alterations of these
mechanisms in PCOS might provide novel therapies.
Most of the studies suggest decreased total brain and total gray
matter volume (GMV) in obesity and type 2 diabetes suggesting a
decline in cognition and other brain functions [15–18]. Increased
GMV is associated with increased brain activity whereas reduced
GMV is associated with deficient function [19]. Detecting
whether there are alterations in brain volumes in women with
PCOS might provide further understanding in appetitive
responses in women with PCOS.
In this study, we hypothesized that total brain and total GMVs
are different in women with PCOS compared to healthy women
and these differences are related to body mass index (BMI) and
appetite-related hormones such as leptin, ghrelin and GLP-1.
Materials and methods
A total of 40 subjects participated in this study. Ten lean and 10
obese PCOS patients were enrolled who presented to the
Endocrinology and Metabolism or Gynecology and Obstetrics
Clinics of Hacettepe University. Ten lean and 10 obese healthy
women volunteered to be in the study comprised the control
groups. Controls had no menstrual irregularities, hirsutism or any
disease and did not use any medication. Ovarian ultrasonography
and hormonal evaluation were performed to exclude the diagnosis
of PCOS in both lean and obese control groups. PCOS diagnosis
was made according to Androgen Excess and PCOS Society (AE-
PCOS Society) criteria [20]. Biochemical and clinical hyperan-
drogenism, oligo-anovulation and polycystic ovaries were defined
as previously described [21]. Obesity was defined as having BMI
30 kg/m2 and being lean was considered to have a BMI between
18.5 and 25 kg/m2 [3]. All women diagnosed with PCOS had
biochemical and/or clinical hyperandrogenism. Oligo-anovulation
was present in 70% of lean PCOS group and 80% of obese PCOS
group, whereas polycystic ovaries were present 100% of lean
PCOS group and 70% in obese PCOS group. Women with any other
endocrine disorder were excluded. Being smoker or ex-smoker,
left-handed, less than a high school graduate and having psychiatric
disorder were other exclusion criteria. Four groups were studied
according to their BMI values and their diagnosis of PCOS, as lean
control, lean PCOS, obese control and obese PCOS.
Measurement of the waist, hip and neck circumference, as well
as weight and height was performed in all subjects. Total fat mass,
fat-free mass and total body water were measured using a
Bioelectrical Impedance Segmental Body Analysis Monitor
(TANITA, BC-418 MA type, Tokyo, Japan). Measurements were
taken in kilograms and percentages. Basal metabolic rate was
calculated through bioimpedance analysis prediction method [22].
All subjects were studied at baseline, during the follicular phase
(days 2–5) of the menstrual cycle. All measurements were made
after 8 h of fasting. For endocrine and metabolic evaluation; total
testosterone (T), dehydroepiandrosterone sulfate (DHEAS), sex
hormone binding globulin (SHBG), fasting insulin, fasting glucose,
fasting lipid profile [triglycerides (TG), high-density lipoprotein
cholesterol (HDL) and low-density lipoprotein cholesterol (LDL)],
as well as alanine aminotransferase, creatinine and complete blood
count, were studied. Free androgen index (FAI¼ [T(mmol/l)/
SHBG (nmol/l)] 100), homeostasis model assessment index-
insulin resistance (HOMA-IR¼ [fasting insulin (uU/ml) fasting
plasma glucose (mg/dl)]/405) and total cholesterol (total
cholesterol¼ [LDL + HDL + (TG/5)] were calculated from the
formulas.
Every individual’s perception of satiety was measured on a
subjective satiety scale (from very hungry to very full) [23].
Mixed-meal tolerance test (MTT) was performed with Abbott
standard oral enteral solution (Abbott Ensure plus; Abbott
Laboratories, Columbus, OH). After an overnight fast, a
standardized mixed meal was given as breakfast within 5 min.
Blood samples were taken at 0, 15, 30, 45, 60, 90, 120 and
180 min to measure fasting levels of leptin and ghrelin and fasting
and meal stimulated levels of GLP-1. Subjects completed a scale
to assess subjective satiety before and during MTT before each
venous sampling. Physical activity and additional food consump-
tion were not allowed during testing.
Venous blood samples were obtained and centrifuged within
2 h, and serum was stored at 80 C. T and insulin concentrations
were measured by chemiluminescent immunoassay kits (Roche
Diagnostics GmbH, Mannheim, Germany). Intra- and interassay
coefficients of variation for T were both55% and for insulin4.3%
and 3.4%, respectively. The concentration of DHEAS was
determined by chemiluminescent immunoassay (Immulite 2000;
Siemens Healthcare Global Eschborn, Germany) and SHBG was
measured by immunoradiometric assay (ZenTech, Angleur,
Belgium) with both intra- and interassay coefficients of vari-
ation510%. TG, LDL and HDL concentrations were measured by
using enzymatic calorimetric kits with intra- and interassay
coefficients of variation of510% and plasma glucose concentra-
tion was determined by the glucose oxidase method (Olympus AU
2700; Beckman Coulter, Inc., Pasadena, CA). Detection of serum
leptin levels was performed using ELISA method (Boster
Immunoleader, EK0437, Pleasanton, CA) with intra- and inter-
assay coefficients of variation510%. Serum ghrelin levels were
measured with ELISA method (Human Ghrelin (total) ELISA,
Millipore Total Ghrelin- EGZRT-89K, St. Charles, MO) with intra-
and interassay coefficients of variation510%. GLP-1 concentra-
tions were also detected with ELISA method (Millipore,
EZGLP1T-36K, St. Charles, MO) with an intraassay coefficient
of variation 1% and interassay coefficient of variation512%.
In order to evaluate structural brain differences, MRI was
performed in all participants on a 1.5 T system equipped with
8-channel phase-array head coil system (Magnetom Symphony
Tim, Siemens, Erlangen, Germany). Imaging protocol applied
whole brain sagittal 3D T1-weighted (W) magnetization prepared
recalled gradient-echo (MPRAGE) (TR/TE/TI;1910/3.5/1100 ms,
BW: 130, Slice thickness: 1 mm, FOV: 195*260, matrix:
192p*256, number of slices: 176) and T2-W axial turbo spin-
echo (TR/TE; 5890/117, BW:130, SL:5/0.75, FOV:220*220,
matrix: 359*448s, number of slices: 25) sequences. Following
the acquisition of the data, these images were reviewed by an
experienced neuroradiologist and MRI physician who were blind
to subject status. For total brain volume analysis, we used
Freesurfer version 5.3.0 (Boston, MA) (http://surfer.nmr.mgh.
harvard.edu/) volumetric segmentation including the removal of
non-brain tissue, using an automated algorithm to segment the
whole brain (including caudate nucleus, ventral diencephalon,
hippocampus and amygdala), motion correction and cortical
surface reconstruction [24]. For the automated segmentation and
labeling of subcortical brain regions, a standard atlas, Talairach
atlas was used and the images were smoothed with Gaussian
blurring kernels. The automated segmentation trades on an affine
rigid linear transformation and defines the location of neighboring
structures. Each region was normalized with intracranial volume.
The relation between these measurements and basal levels of
leptin and ghrelin as well as basal and stimulated levels of GLP-1
were investigated with Spearman’s correlation analysis.
Statistical analysis
Statistical analyses were performed with IBM SPSS Statistics for
Mac version 20 (IBM Corp. Released 2011, Armonk, NY).
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Numeric variables were summarized as median and minimum and
maximum values. Categorical variables were evaluated with cross
table analysis and shown numerically with a percentage. Mann–
Whitney U test was used for all pairwise comparisons. The area
under the curve (AUC) for SI results and GLP-1 measurements
were calculated using the trapezoidal formula. The correlation
between volumes of the specified structures and hormonal
measurements were detected using Spearman’s correlation coef-
ficient. Because of the statistical difference of age in lean PCOS
and control groups, the age-adjusted statistical analysis was
performed in all comparisons of these two groups. p50.05 was
considered statistically significant. Power analysis suggested that
10 people per study group achieved 95.02% power to detect a
standardized effect size of 0.45 between groups, in the total brain
volume (cm3) with a¼ 0.05. Power calculation was conducted
with the NCSS-PASS software (Kaysville, UT).
Results
Baseline characteristics of study groups
Anthropometric measurements, body composition properties and
hormonal and biochemical parameters are presented in Table 1.
Although all women were in childbearing age, the mean age of
lean PCOS group was lower than lean controls (p50.01)
(Table 1). There were no difference between lean PCOS and
lean control groups in terms of height, weight, BMI and waist and
neck circumference, but lean PCOS group had a significantly
higher waist/hip ratio than the lean control group (p¼ 0.023),
(Table 1). TANITA measurements were similar between two
groups. T, DHEAS and FAI values, as well as modified Ferriman–
Gallwey (mF-G) score, were higher (p50.01 for all), whereas
SHBG levels were lower (p50.01) in lean PCOS compared to
controls. There were no differences between two groups in terms
of lipid profile and fasting glucose values but fasting insulin
values were higher in lean PCOS group (p¼ 0.029) (Table 1).
Obese PCOS group and obese controls had similar anthropo-
metric measurements (Table 1). T, FAI, DHEAS and mF-G scores
were significantly higher in obese PCOS group (p50.01 for all),
whereas SHBG, lipid profile, fasting glucose and insulin levels
were similar in both groups.
Comparison of volumetric measurements
When obese PCOS and obese controls were compared, total brain
volume (brain segmentation volume without ventricles) and total
GMV were found to be significantly lower in obese PCOS group
compared to obese controls (p¼ 0.023 and p¼ 0.048, respectively)
(Table 1). Additionally, reduced volume was also observed in left
ventral diencephalon (p¼ 0.018), left nucleus caudatus (p¼ 0.043)
and left and right hippocampus in obese PCOS group (p¼ 0.015
and p¼ 0.042, respectively).
In the lean groups, the age-adjusted statistical analysis revealed
no statistically significant difference in total brain volume and
total GMV, however, lean women with PCOS had significantly
lower GMV in left amygdala compared to controls (p¼ 0.028).
Comparison of basal and meal stimulated hormone levels,
satiety and determination of correlation with volumetric
measurements
No significant differences were detected between lean PCOS and
lean control groups and between obese PCOS and obese control
groups in terms of basal serum leptin, ghrelin and GLP-1 levels
(Table 1). Meal stimulated GLP-1 levels were similar in obese
PCOS and healthy obese groups (p¼ 0.822). Even though there
was a tendency for reduced levels of GLP-1 toward the end of the
test in lean PCOS compared to lean controls this difference did
not reach statistical significance.
Lean PCOS and lean control groups and obese PCOS and
obese control groups did not differ when AUC calculations of SI
values were considered (p¼ 0.985 and p¼ 0.579, respectively)
(Table 1).
No significant correlations were found between volume
reduction of brain areas and fasting leptin, ghrelin, GLP-1 and
meal stimulated GLP-1 levels.
Discussion
Our study indicates that obese women with PCOS have a lower
total brain and total GMVs than age- and BMI-matched obese
controls. Most studies suggest decreased total brain and total
GMV in obesity and type 2 diabetes [15–18], although not all










Age 20 (18–25) 26.5 (25–40) 50.01 28.5 (18–34) 32 (20–39) NS
Height (m) 1.61 (1.51–1.68) 1.63 (1.55–1.70) NS 1.58 (1.55–1.77) 1.65 (1.54–1.74) NS
Weight (kg) 55.1 (48.7–67) 54.2 (47.9–68.9) NS 89.7 (77–123.6) 103.6 (85.5–125.9) NS
BMI (kg/m2) 21.0 (18.6–24.9) 20.5 (19.1–24.8) NS 34.2 (30.8–44.3) 38.2 (30.8–47.5) NS
Waist circumference (cm) 68.5 (61–82) 65.5 (60–70) NS 103.5 (90–130) 108 (91–130) NS
Waist/hip ratio 0.73 (0.65–0.81) 0.70 (0.64–0.73) 0.023 0.84 (0.79–1.12) 0.83 (0.74–0.93) NS
Neck circumference (cm) 30.0 (28–35) 30.5 (28–33) NS 38 (34–41) 38 (35–41) NS
Fat mass (%) 22.8 (13.5–33.6) 22.2 (16–29.6) NS 43.2 (38–51.4) 43.4 (35.5–52.6) NS
BMR (kcal) 1306 (1226–1504) 1265 (1193–1495) NS 1589 (1472–2092) 1792 (1618–2006) NS
Fasting plasma glucose (mg/dl) 84.5 (82–93) 88 (74–101) NS 100 (84–115) 97 (79–110) NS
Insulin (mIU/ml) 7.1 (5.1–11.1) 4.4 (2–9.6) 0.029 19.2 (10.6–27.7) 15 (9–26.9) NS
HOMA-IR 1.5 (1.0–2.3) 1.04 (0.4–1.95) 0.029 4.4 (2.6–7.2) 3.3 (1.8–6.3) NS
Leptin 0 min (ng/ml) 12.4 (2.9–52) 7.4 (5–38.6) NS 41.6 (23.6–61) 45.9 (18.9–65) NS
Ghrelin 0 min (pg/ml) 319 (234–594) 353 (204–1104) NS 245 (204–359) 221 (202–279) NS
GLP-1 0 min (pM) 25.5 (18.2–65.1) 34.2 (20.4–43.7) NS 57.6 (10.8–73.1) 50.7 (34–66.8) NS
GLP-1 AUC 6516 (3583–10 380) 7125 (4144–9866) NS 9739 (3104–21 620) 11145 (7728–16 070) NS
Satiety Index AUC 735 (315–1110) 750 (210–1005) NS 851 (353–1230) 619 (293–1118) NS
Total brain volume (cm3) 1090 (998–1249) 1104 (1040–1201) NS 1027 (972–1121) 1091 (984–1296) 0.023
Total gray matter volume (cm3) 634 (563–724) 636 (579–680) NS 601 (538–665) 636 (551–739) 0.048
AUC: area under the curve; BMI: body mass index; BMR: basal metabolic rate; GLP-1: glucagon-like peptide-1; HOMA-IR: homeostasis model
assessment index-insulin resistance; NS: non-significant; PCOS: polycystic ovary syndrome.
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agree [8,25]. Those reporting differences frequently involved men
and women with older age (from 45 up to 75) [15,17,18]. Taki
et al. [17] showed decreased total brain volumes in obese men but
not in women and linked this finding to different fat distribution
patterns of men and women, with visceral fat predominating in
men and subcutaneous fat predominating in women. Increased
visceral fat is associated with increased risk of metabolic
syndrome and women with PCOS are known to be prone to
increase visceral fat [26]. Castellano et al. [27] showed similar
total brain volumes in lean women with PCOS compared to BMI-
matched healthy counterparts, consistent with our findings in lean
women with PCOS. Our results suggest that when obesity is
accompanied with PCOS, decreased brain volume could be
observed at early ages that is usually observed in older patients
with obesity and/or diabetes.
Although our primary aim was to detect total brain volumetric
differences, we have also made secondary analyses related with
regional brain volumes taking into account previous data
including diabetes and obesity studies. We have found volumetric
reductions in some gray matter areas related with appetite and
appetite-related behavior in obese women with PCOS when
compared to obese controls such as; left ventral diencephalon
(includes hypothalamus), left nucleus caudatus and bilateral
hippocampus. These areas are involved in appetite regulation,
eating behavior and energy balance and are also important to
include receptors of appetite hormones or to show signal changes
due to hormonal effects by using fMRI techniques [9,10].
Generally, it could be inferred that structural and functional
differences in brain regions related with sensory processing,
pleasure, memory and inhibitor control could cause an increase in
food consumption in obese individuals. Also, metabolic changes
seen in obesity could trigger undesirable changes in brain tissue
[28]. Hypothalamus, nucleus caudatus and hippocampus volumes
were reported to be inversely correlated with BMI [8,29,30]. Also,
hippocampal volumes were shown to be decreased in patients
with type 2 diabetes [16]. In the presence of both obesity and
PCOS, food intake and appetite regulation may be altered more
evidently through homeostatic and hedonic systems. We have also
observed reduced GMV in left amygdala in our lean PCOS group
compared to lean controls. Lower amygdala volume was reported
to be associated with altered reward susceptibility, which could
increase the risk for future weight gain [31]. However, we were
not able to explain the reason of volumetric differences not seen
bilaterally but on one side. To the best of our knowledge, no
convincing explanation is available in the literature, although
there are studies finding different results for the left and right
regions [32,33]. Although we have found statistically significant
regional volumetric differences in both groups, these secondary
results can only be taken as hypothesis generating preliminary
findings for women with PCOS.
In our study, we have also looked at whether brain structural
differences in PCOS are linked to satiety, measured by a visual
analog scale and hormonal alterations. SI was similar between the
groups and did not correlate with structural differences. Basal
leptin, ghrelin and GLP-1 were not significantly different in
PCOS patients compared to their BMI-matched healthy counter-
parts. Meal stimulated GLP-1 levels were similar in obese PCOS
and healthy obese groups whereas there was a tendency to
reduced levels of GLP-1 toward the end of the test in lean PCOS
compared to lean controls. Nevertheless, we have failed to detect
any significant correlation between hormone levels and structural
alterations in brain regions. There are no studies in PCOS looking
at structural or functional changes in brain and alterations in the
appetite-related gut and adipose hormones. Leptin was reported to
be positively associated with hypothalamus volumes in obese
individuals [32]. Peripheral levels might not reflect central levels
of hormones in the CNS or tissue levels [34], also potentially
other hormones that have not been measured in our study such as
peptide YY, cholecystokinin, gastric inhibitory peptide might be
involved in linking gut-brain axis in PCOS.
Limitations of our study include the relatively small sample
size, which might have precluded us to detect minor differences
between the groups. Also, the cross-sectional design of our study
does not allow us to interpret whether our findings are cause or
consequence of obesity and PCOS. Finally, the volumetric
analysis is not able to give detailed information about the
micro-architectural structure of brain regions.
In conclusion, we have observed a reduction in total brain
volume and total GMV, as well as gray matter reductions in some
appetite-related areas. These alterations did not show any
association with basal peripheral levels of leptin, ghrelin and
GLP-1 and meal stimulated GLP-1 levels. Further studies with
larger sample size are needed to assess the functional relevance of
structural alterations in brain regions of PCOS.
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